Effects of phosphodiesterase‐5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial

• Published in: BJU international 2010-10, Vol.106 (8), p.1181-1185
• Main Authors: Dimitriadis, Fotios, Tsambalas, Stavros, Tsounapi, Panagiota, Kawamura, Hiroshi, Vlachopoulou, Evlalia, Haliasos, Nikolaos, Gratsias, Stavros, Watanabe, Takeshi, Saito, Motoaki, Miyagawa, Ikuo, Sofikitis, Nikolaos
• Format: Article
• Language: English
• Subjects: Analysis of Variance; Biological and medical sciences; Carnitine; Humans; Imidazoles; Insulin - blood; Insulin - metabolism; Insulin Secretion; Leydig cell; Leydig Cells - drug effects; Leydig Cells - metabolism; Male; Medical sciences; Nephrology. Urinary tract diseases; Oligospermia - blood; Oligospermia - drug therapy; PDE5 inhibitors; Phosphodiesterase 5 Inhibitors - therapeutic use; Piperazines; Proteins - metabolism; Purines; Sildenafil Citrate; Sperm Count; Sperm Motility; sperm quality; Sulfones; testis; Treatment Outcome; Triazines; Vardenafil Dihydrochloride
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/j.1464-410X.2010.09243.x

Study Type – Therapy (RCT)
Level of Evidence 1b OBJECTIVE To evaluate the effects of phosphodiesterase‐5 inhibitors (PDE5‐i) on Leydig cell secretory function (LCSF). PATIENTS AND METHODS In all, 75 men with oligoasthenospermia were treated daily for 12 weeks with either vardenafil (23 men, group A), sildenafil (25 men, group B) or l‐carnitine (26 men, group C); a further group of 22 men with oligoasthenospermia (group D) received no treatment. Serum levels of insulin‐like‐3 peptide (INSL3) were evaluated before and after the end of the treatment in each of groups A, B and C, respectively. Serum INSL3 levels were measured in each participant of group D before and after the 12‐week experimental period. RESULTS Within group A and B, the peripheral serum mean INSL3 concentration, sperm concentration, percentage of motile spermatozoa, and percentage of morphologically normal spermatozoa were significantly greater after PDE5‐i treatment than before. CONCLUSION We suggest that PDE5‐i enhances LCSF, as the mean INSL3 concentration was significantly greater after PDE5‐i administration than before, within groups A and B. This enhancement in LCSF might contribute to the increase in sperm concentration and sperm motility after administration of PDE5‐i.